156 related articles for article (PubMed ID: 16760502)
21. PHARMACOKINETICS OF PRIMAQUINE PHOSPHATE AFTER A SINGLE ORAL ADMINISTRATION TO AFRICAN PENGUINS (
Carag JH; Sander SJ; Kottyan J; Phillips J; Brubaker J; Cruz-Espindola C; Boothe D; Bronson E
J Zoo Wildl Med; 2021 Apr; 52(1):75-80. PubMed ID: 33827163
[TBL] [Abstract][Full Text] [Related]
22. The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China.
Qingjun L; Jihui D; Laiyi T; Xiangjun Z; Jun L; Hay A; Shires S; Navaratnam V
Bull World Health Organ; 1998; 76 Suppl 1(Suppl 1):21-7. PubMed ID: 9763719
[TBL] [Abstract][Full Text] [Related]
23. [Plasmodium vivax malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004].
Carmona-Fonseca J; Alvarez G
Biomedica; 2006 Sep; 26(3):353-65. PubMed ID: 17175999
[TBL] [Abstract][Full Text] [Related]
24. Co-administration of ritonavir and primaquine decreases plasma concentration of primaquine: single- and multiple-dose study in the rats.
Louisa M; Soetikno V; Nafrialdi ; Setiabudy R; Suyatna FD
Acta Med Indones; 2012 Oct; 44(4):273-9. PubMed ID: 23314966
[TBL] [Abstract][Full Text] [Related]
25. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria.
Schwartz E; Regev-Yochay G; Kurnik D
Am J Trop Med Hyg; 2000 Mar; 62(3):393-5. PubMed ID: 11037784
[TBL] [Abstract][Full Text] [Related]
26. Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment.
Carmona-Fonseca J; Alvarez G; Maestre A
Am J Trop Med Hyg; 2009 Feb; 80(2):188-93. PubMed ID: 19190211
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo evaluation of a primaquine prodrug without red blood cell membrane destabilization property.
Davanço MG; Campos ML; Nogueira MA; Campos SL; Marques RV; dos Santos JL; Chin CM; da Fonseca LM; Peccinini RG
Biopharm Drug Dispos; 2012 Nov; 33(8):437-45. PubMed ID: 22899089
[TBL] [Abstract][Full Text] [Related]
28. Enantioselective pharmacokinetics of primaquine in healthy human volunteers.
Tekwani BL; Avula B; Sahu R; Chaurasiya ND; Khan SI; Jain S; Fasinu PS; Herath HM; Stanford D; Nanayakkara NP; McChesney JD; Yates TW; ElSohly MA; Khan IA; Walker LA
Drug Metab Dispos; 2015 Apr; 43(4):571-7. PubMed ID: 25637634
[TBL] [Abstract][Full Text] [Related]
29. Treatment of acute vivax malaria with tafenoquine.
Nasveld P; Kitchener S
Trans R Soc Trop Med Hyg; 2005 Jan; 99(1):2-5. PubMed ID: 15550254
[TBL] [Abstract][Full Text] [Related]
30. Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India.
Dua VK; Sharma VP
Ann Trop Med Parasitol; 2001 Oct; 95(7):655-9. PubMed ID: 11784418
[TBL] [Abstract][Full Text] [Related]
31. Repeated Plasmodium vivax malaria relapses in a Peruvian sailor.
McFarland AP; Sanchez JF; Mercado A; Ventocilla JA; Cavalcanti S; Gonzalez S; Lescano AG
Malar J; 2015 Dec; 14():478. PubMed ID: 26620122
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.
Moore BR; Salman S; Benjamin J; Page-Sharp M; Robinson LJ; Waita E; Batty KT; Siba P; Mueller I; Davis TM; Betuela I
Antimicrob Agents Chemother; 2014; 58(1):432-9. PubMed ID: 24189254
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
34. Levels of primaquine and carboxyprimaquine in patients with malaria vivax from the Brazilian Amazon basin.
Mello AGNC; Vieira MVDF; Sena LWP; Paixão TPD; Pinto ACG; Grisólia DPA; Silva MT; Vieira JLF
Rev Inst Med Trop Sao Paulo; 2018 Oct; 60():e66. PubMed ID: 30379233
[TBL] [Abstract][Full Text] [Related]
35. Sex differences in CYP3A activity using intravenous and oral midazolam.
Chen M; Ma L; Drusano GL; Bertino JS; Nafziger AN
Clin Pharmacol Ther; 2006 Nov; 80(5):531-8. PubMed ID: 17112809
[TBL] [Abstract][Full Text] [Related]
36. Alteration of platelet counts and lipid profiles after treatment of acute Plasmodium vivax.
Kim JS; Oh JS; Chang EA; Bae SY; Nam DH; Lee CH; Yang JH; Lee CK; Lee WJ; Kim HC; Klein TA; Lim CS; Kim YK
Acta Trop; 2008 Apr; 106(1):39-43. PubMed ID: 18304498
[TBL] [Abstract][Full Text] [Related]
37. [New use of primaquine for malaria].
Oliver M; Simon F; de Monbrison F; Beavogui AH; Pradines B; Ragot C; Moalic JL; Rapp C; Picot S
Med Mal Infect; 2008 Apr; 38(4):169-79. PubMed ID: 18395381
[TBL] [Abstract][Full Text] [Related]
38. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.
Hill DR; Baird JK; Parise ME; Lewis LS; Ryan ET; Magill AJ
Am J Trop Med Hyg; 2006 Sep; 75(3):402-15. PubMed ID: 16968913
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction.
Kulkarni SP; Shah SR; Kadam PP; Sridharan K; Hase NK; Shetty PP; Thatte UM; Gogtay NJ
Indian J Pharmacol; 2013; 45(4):330-3. PubMed ID: 24014905
[TBL] [Abstract][Full Text] [Related]
40. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine.
Singh KK; Vingkar SK
Int J Pharm; 2008 Jan; 347(1-2):136-43. PubMed ID: 17709216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
